The Association Between Azathioprine Genetic Polymorphisms, Clinical Efficacy and Adverse Drug Reactions Among Egyptian Patients with Autoimmune Diseases

被引:1
作者
Abuelsoud, Nermeen [1 ,2 ]
Fayed, Hala [3 ]
Elkateeb, Engy [4 ]
机构
[1] British Univ Egypt, Fac Pharm, Dept Clin Pharm Practice, Cairo, Egypt
[2] Egyptian Russian Univ, Fac Pharm, Dept Pharm Practice Clin Pharm, Cairo, Egypt
[3] Cairo Univ, Kasr Alaini Univ Hosp, Fac Med, Dept Rheumatol & Rehabil, Cairo, Egypt
[4] Cairo Univ, Kasr Alaini Univ Hosp, Fac Med, Dept Chem & Clin Pathol, Cairo, Egypt
关键词
azathioprine; genetic polymorphisms; autoimmune diseases; Egyptian patients; THIOPURINE METHYLTRANSFERASE GENOTYPE; IMPLEMENTATION CONSORTIUM GUIDELINES; CROHNS-DISEASE; ALLELES; TPMT; PHARMACOGENETICS; MERCAPTOPURINE; INHERITANCE; PHARMACOLOGY; FREQUENCIES;
D O I
10.2147/PGPM.S285033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: The study aimed to detect the frequencies of allelic variants (TPMT*3A, TPMT*3C, and TPMT*3G) in the TPMT genes in the Egyptian population and assess the association between TPMT polymorphisms and azathioprine (AZA)-clinical efficacy and adverse drug reactions among Egyptian patients with autoimmune diseases. Design: A prospective, observational single-center clinical trial. Setting: Rheumatology and Rehabilitation Department, Kasr Alainy University Hospital, Faculty of Medicine, Cairo University. Patients: Patients attending Kasr Alainy Rheumatology Outpatient Clinic between December 1, 2017 and June 30, 2019 were included in the study after signing a consent form. TPMT genetic polymorphisms were detected for all patients, and the association between polymorphisms presence and azathioprine's clinical efficacy and adverse drug reactions were determined. Results: A total of 150 patients with a mean age of 35.85 years were enrolled in this study. About 72% of patients were heterozygous in the TPMT*3 G460A and TPMT*3 A719G mutant alleles and 81% were wild type in the TPMT*2 G238C mutant allele. Abnormal liver function tests were detected in 42% of patients. Myelosuppression was presented as anemia which was detected in 63% of patients, leucopenia in 51%, and thrombocytopenia in 25% of patients. AZA clinical failure has occurred in 50% of patients where AZA was discontinued or shifted to another drug which occurred in 45% of patients. Myelosuppression rates were higher in homozygous patients in the three mutant alleles, but statistically significant in TPMT*2 G238C while not statistically significant in TPMT*3 G460A and TPMT*3 A719G. Females had a higher risk of immunosuppression than males (p-value 0.031). Conclusion: The study provided an overview of the genomic variations in the Egyptian population. Routine TPMT genotyping prior to the initiation of AZA therapy should be considered.
引用
收藏
页码:179 / 187
页数:9
相关论文
共 34 条
  • [1] Thiopurine methyltransferase alleles in British and Ghanaian populations
    Ameyaw, MM
    Collie-Duguid, ESR
    Powrie, RH
    Ofori-Adjei, D
    McLeod, HL
    [J]. HUMAN MOLECULAR GENETICS, 1999, 8 (02) : 367 - 370
  • [2] Guidelines for prescribing azathioprine in dermatology
    Anstey, AV
    Wakelin, S
    Reynolds, NJ
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 (06) : 1123 - 1132
  • [3] Nomenclature for alleles of the thiopurine methyltransferase gene
    Appell, Malin L.
    Berg, Jonathan
    Duley, John
    Evans, William E.
    Kennedy, Martin A.
    Lennard, Lynne
    Marinaki, Tony
    McLeod, Howard L.
    Relling, Mary V.
    Schaeffeler, Elke
    Schwab, Matthias
    Weinshilboum, Richard
    Yeoh, Allen E. J.
    McDonagh, Ellen M.
    Hebert, Joan M.
    Klein, Teri E.
    Coulthard, Sally A.
    [J]. PHARMACOGENETICS AND GENOMICS, 2013, 23 (04) : 242 - 248
  • [4] Azathioprine and anti-TNFα therapies in Crohn's disease:: a review of pharmacology, clinical efficacy and safety
    Arnott, IDR
    Watts, D
    Satsangi, J
    [J]. PHARMACOLOGICAL RESEARCH, 2003, 47 (01) : 1 - 10
  • [5] Baker Danial E, 2003, Rev Gastroenterol Disord, V3, P150
  • [6] Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine
    Campbell, S
    Kingstone, K
    Ghosh, S
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (03) : 389 - 398
  • [7] Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations
    Chang, JG
    Lee, LS
    Chen, CM
    Shih, MC
    Wu, MC
    Tsai, FJ
    Liang, DC
    [J]. PHARMACOGENETICS, 2002, 12 (03): : 191 - 195
  • [8] The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations
    Collie-Duguid, ESR
    Pritchard, SC
    Powrie, RH
    Sludden, J
    Collier, DA
    Li, T
    McLeod, HL
    [J]. PHARMACOGENETICS, 1999, 9 (01): : 37 - 42
  • [9] Das Pranab K, 2011, Immunotherapy, V3, P147, DOI 10.2217/imt.10.102
  • [10] Pharmacogenomics in inflammatory bowel disease
    Egan, LJ
    Derijks, LJJ
    Hommes, DW
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (01) : 21 - 28